89 related articles for article (PubMed ID: 2171561)
21. In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.
Hong WS; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Takahashi H; Nakano H; Nakagawa K; Twentyman PR
Jpn J Cancer Res; 1987 Nov; 78(11):1274-80. PubMed ID: 3121562
[TBL] [Abstract][Full Text] [Related]
22. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
23. In vitro chemosensitivity of human lung cancer cell lines.
Ruckdeschel JC; Carney DN; Oie HK; Russell EK; Gazdar AF
Cancer Treat Rep; 1987; 71(7-8):697-704. PubMed ID: 3038314
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of magainin analogues against human lung cancer cell lines.
Ohsaki Y; Gazdar AF; Chen HC; Johnson BE
Cancer Res; 1992 Jul; 52(13):3534-8. PubMed ID: 1319823
[TBL] [Abstract][Full Text] [Related]
25. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
Yu Q; Mirski SE; Sparks KE; Cole SP
Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
[TBL] [Abstract][Full Text] [Related]
26. [Anti-neoplastic activity of a human recombinant tumor necrosis factor (Hu-rec-TNF) alone or in combination with human recombinant gamma-interferon, doxorubicin or cis-platinum on a human renal cell carcinoma line].
Gohji K; Hamami G; Kamidono S
Hinyokika Kiyo; 1987 Mar; 33(3):329-35. PubMed ID: 3113191
[TBL] [Abstract][Full Text] [Related]
27. The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines.
Balcer-Kubiczek EK; Attarpour M; Edelman MJ
Cancer Chemother Pharmacol; 2007 May; 59(6):781-7. PubMed ID: 16957930
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
30. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
[TBL] [Abstract][Full Text] [Related]
31. Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity.
Hida T; Ariyoshi Y; Kuwabara M; Sugiura T; Takahashi T; Takahashi T; Hosoda K; Niitsu Y; Ueda R
Jpn J Clin Oncol; 1993 Feb; 23(1):14-9. PubMed ID: 8384671
[TBL] [Abstract][Full Text] [Related]
32. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
[TBL] [Abstract][Full Text] [Related]
33. The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines.
Ko D; Raaphorst GP; Feeley MM; Danjoux CE; Maroun JA; Evans WK
Anticancer Res; 1991; 11(1):235-9. PubMed ID: 1850216
[TBL] [Abstract][Full Text] [Related]
34. Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines.
Giaccone G; Kadoyama C; Maneckjee R; Venzon D; Alexander RB; Gazdar AF
Int J Cancer; 1990 Aug; 46(2):326-9. PubMed ID: 2166714
[TBL] [Abstract][Full Text] [Related]
35. Effects of interferons and tumour necrosis factor-alpha on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line.
Suarez Pestana E; Björklund G; Larsson R; Nygren P; Nilsson K; Bergh J
Acta Oncol; 1996; 35(4):473-8. PubMed ID: 8695164
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
[TBL] [Abstract][Full Text] [Related]
37. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
Binaschi M; Capranico G; De Isabella P; Mariani M; Supino R; Tinelli S; Zunino F
Int J Cancer; 1990 Feb; 45(2):347-52. PubMed ID: 2154411
[TBL] [Abstract][Full Text] [Related]
38. A method for determining schedule dependency in tissue culture.
Wampler GL; Carter WH; Campbell ED; Keefe PA
J Biopharm Stat; 1991; 1(2):261-86. PubMed ID: 1668959
[TBL] [Abstract][Full Text] [Related]
39. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Mori K; Yazawa Y; Tsunoda S
Cancer Chemother Pharmacol; 1999; 44(5):381-8. PubMed ID: 10501911
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies.
Alexander RB
Cancer Treat Res; 1992; 59():105-20. PubMed ID: 1347688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
